Hylenex us loss of exclusivity?

“Hylenex” (hyaluronidase injection) has had an evolving exclusivity/market exclusivity situation, but the key point is this:

What “loss of exclusivity” usually means

When a brand drug loses exclusivity, generic or biosimilar/authorized alternatives can be approved and marketed sooner (depending on patent status, FDA exclusivity periods, and whether other barriers remain). After that, multiple competitors may enter and the brand’s market share can decline.

Hylenex specifically

• Hylenex (hyaluronidase) is an older, widely available product.
• Its FDA market exclusivity has long been expired (so “loss of exclusivity” is not typically a single recent event like it is for brand-new drugs).
• In practice, Hylenex commonly faces generic/alternative availability pressures rather than a single, newly expired exclusivity window.

To give you the exact date/statement you need

“Loss of exclusivity” can refer to different things (FDA exclusivity, patent expiry, or specific product strength/NDC). If you tell me:

1. the strength (e.g., 1500 units/15 mL or other), and
2. the NDC or whether you mean Hylenex brand vs. any generic, and
3. whether you want FDA exclusivity or patent status,

…I can narrow it down to the correct exclusivity/patent timeline.

Do you want the FDA exclusivity loss date, or are you asking whether generics are currently available?